US · INO · BIOTECHNOLOGY
Inovio Pharmaceuticals, Inc. (INO) intrinsic value and stock valuation
$1.76as of 2026-11-21 · Mkt cap 46.78M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Inovio Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values INO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from INO’s statements →
Inovio Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $70K | $220K | $830K | $10.3M | $1.77M |
| Operating income | -$-86.82M | -$-112.4M | -$-143.94M | -$-267.57M | -$-301.22M |
| Net income | -$-84.95M | -$-107.25M | -$-135.12M | -$-279.82M | -$-303.66M |
| EPSd | -$-1.81M | -$-3.95M | -$-6.09M | -$-14.07M | -$-17.45M |
| Operating cash flow | -$-88.63M | -$-104.08M | -$-124.37M | -$-216.22M | -$-215.71M |
| Capital expenditure | -$-290K | -$-490K | -$-320K | -$-970K | -$-1.23M |
| Free cash flow | -$-88.92M | -$-104.56M | -$-124.69M | -$-217.18M | -$-216.94M |
| Total assets | $74.3M | $113.2M | $171M | $348.5M | $495.9M |
| Total debt | $9.37M | $11.9M | $30.2M | $32.1M | $33M |
| Net debt | -$-34.91M | -$-53.95M | $15.9M | -$-14.25M | -$-38.12M |
| Total equity | $24.1M | $68.5M | $117.4M | $222.4M | $399.7M |
| Cash and short-term investments | $58.5M | $94.1M | $145.3M | $253M | $401.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $70K | $220K | $830K | $10.3M | $1.77M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $70K | $220K | $830K | $10.3M | $1.77M |
| Research and development expenses | $54.2M | $75.6M | $86.7M | $187.7M | $249.2M |
| Selling, general and administrative expenses | $32.7M | $37M | $47.6M | $90.2M | $53.8M |
| Other expenses | $0.00 | $0.00 | $10.5M | $0.00 | $0.00 |
| Operating expenses | $86.9M | $112.6M | $144.8M | $277.8M | $303M |
| Cost and expenses | $86.9M | $112.6M | $144.8M | $277.8M | $303M |
| Interest income | $2.42M | $4.77M | $8.13M | $4.78M | $3.36M |
| Interest expense | $0.00 | $180K | $1.22M | $1.25M | $1.94M |
| Depreciation and amortization | $2.99M | $3.13M | $3.5M | $5.5M | $4.73M |
| Ebitda | -$-81.96M | -$-103.95M | -$-130.39M | -$-270.9M | -$-296.56M |
| Operating income | -$-86.82M | -$-112.4M | -$-143.94M | -$-267.57M | -$-301.22M |
| Total other income/expenses, net | $1.88M | $5.14M | $8.82M | -$-12.24M | -$-2.44M |
| Income before tax | -$-84.95M | -$-107.25M | -$-135.12M | -$-279.82M | -$-303.66M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$-84.95M | -$-107.25M | -$-135.12M | -$-279.82M | -$-303.66M |
| Weighted average shares outstanding | $46.9M | $27.2M | $22.2M | $19.9M | $17.4M |
| Weighted average diluted shares outstanding | $46.9M | $27.2M | $22.2M | $19.9M | $17.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $58.5M | $94.1M | $145.3M | $253M | $401.3M |
| Net receivables | $0.00 | $1.2M | $2.41M | $11.7M | $8.03M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $61.1M | $97.8M | $153.1M | $315.2M | $448.4M |
| Property, plant and equipment, net | $9.07M | $11.8M | $14.5M | $18M | $29M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $12.6M | $13.1M |
| Long-term investments | $2.1M | $1.61M | $2.78M | $2.01M | $3.91M |
| Total non-current assets | $13.2M | $15.4M | $17.8M | $33.3M | $47.5M |
| Total assets | $74.3M | $113.2M | $171M | $348.5M | $495.9M |
| Accounts payable | $2.62M | $6.44M | $4.65M | $21.1M | $28M |
| Short-term debt | $2.82M | $2.5M | $19.2M | $2.8M | $2.6M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $20K |
| Total current liabilities | $43.7M | $35.3M | $42.6M | $96.9M | $65.7M |
| Long-term debt | $6.55M | $9.37M | $11M | $29.3M | $30.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $60K |
| Total non-current liabilities | $6.55M | $9.37M | $11M | $29.3M | $30.5M |
| Capital lease obligations | $9.37M | $11.9M | $13.4M | $15.5M | $18.1M |
| Total liabilities | $50.2M | $44.7M | $53.6M | $126.2M | $96.3M |
| Common stock | $70K | $40K | $20K | $20K | $220K |
| Retained earnings | -$-1.82B | -$-1.73B | -$-1.62B | -$-1.49B | -$-1.21B |
| Accumulated other comprehensive income (loss) | -$-640K | -$-680K | -$-660K | -$-700K | -$-280K |
| Total equity | $24.1M | $68.5M | $117.4M | $222.4M | $399.7M |
| Total investments | $16.3M | $29.9M | $133.8M | $208.7M | $334.1M |
| Total debt | $9.37M | $11.9M | $30.2M | $32.1M | $33M |
| Net debt | -$-34.91M | -$-53.95M | $15.9M | -$-14.25M | -$-38.12M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-84.95M | -$-107.25M | -$-135.12M | -$-279.82M | -$-303.66M |
| Depreciation and amortization | $2.99M | $3.13M | $3.5M | $5.5M | $4.73M |
| Stock-based compensation | $3.76M | $6.6M | $11.1M | $22.6M | $26.3M |
| Change in working capital | -$-9.22M | -$-2.66M | -$-10.26M | $19.8M | $50.4M |
| Accounts receivable | $0.00 | $1.21M | $9.33M | -$-3.71M | $11M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-6.42M | -$-3.37M | -$-45.99M | $32.6M | $26.1M |
| Net cash provided by operating activities | -$-88.63M | -$-104.08M | -$-124.37M | -$-216.22M | -$-215.71M |
| Investments in property, plant and equipment | -$-290K | -$-490K | -$-320K | -$-970K | -$-1.23M |
| Acquisitions, net | $0.00 | $0.00 | $6.22M | -$-2M | $0.00 |
| Net cash used for investing activities | $14M | $104.1M | $87.4M | $109.6M | -$-175.34M |
| Common stock issued | $53.2M | $68.3M | $5.46M | $83M | $209.4M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $53.1M | $51.5M | $5M | $81.8M | $211.5M |
| Net change in cash | -$-21.54M | $51.5M | -$-32.02M | -$-24.81M | -$-179.58M |
| Cash at end of period | $44.3M | $65.8M | $14.3M | $46.3M | $71.1M |
| Operating cash flow | -$-88.63M | -$-104.08M | -$-124.37M | -$-216.22M | -$-215.71M |
| Capital expenditure | -$-290K | -$-490K | -$-320K | -$-970K | -$-1.23M |
| Free cash flow | -$-88.92M | -$-104.56M | -$-124.69M | -$-217.18M | -$-216.94M |
Line items
Line items
Line items
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
- CEO
- Jacqueline E. Shea
- Employees
- 112
- Beta
- 1.49
Explore
Frequently asked questions
What is the intrinsic value of Inovio Pharmaceuticals, Inc. (INO)?
Inovio Pharmaceuticals, Inc. (INO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is INO undervalued?
INO trades at a price of $1.76 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.